Advertisement
Global  

“News neutrality by unbiased coverage”
One News Page
> >

Gilead to Present Wide-Ranging New Data on Treatment and Diagnosis of Liver Diseases at The Liver Meeting® 2018

Business Wire Thursday, 11 October 2018 ()
Gilead to Present Wide-Ranging New Data on Treatment and Diagnosis of Liver Diseases at The Liver Meeting® 2018FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that data from the company’s liver disease research and development programs in nonalcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC), hepatitis B virus (HBV) infection and hepatitis C virus (HCV) infection will be presented at The Liver Meeting® 2018 in San Francisco from November 9-13, 2018. The data reflect Gilead’s ongoing commitment to advancing the care of patients with serious l
0
shares
ShareTweetSavePostSend
 

Recent related news from verified sources

Organovo to Present New Preclinical Data on 3D Bioprinted Human Liver Tissues for the Treatment of Tyrosinemia I at the Liver Meeting® 2018 (AASLD)

SAN DIEGO, Oct. 15, 2018 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ:ONVO) (“Organovo”), a biotechnology company pioneering the development of 3D...
GlobeNewswire - Press ReleasesAlso reported by •Business Wire

Cidara Therapeutics to Present New Rezafungin Data at the 2018 Hot Topics in Infectious Diseases Conference

Cidara Therapeutics to Present New Rezafungin Data at the 2018 Hot Topics in Infectious Diseases Conference
SAN DIEGO--(BUSINESS WIRE)--Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today...
Business Wire - Press Releases

Pharmaxis receives positive results from LOXL2 clinical trial

Pharmaxis Ltd (ASX:PXS) has received positive results from the phase I clinical trial for the first of its LOXL2 inhibitor compounds being developed to treat...
Proactive Investors - Business

Novartis announces presentation of new Lutathera® NETTER-1 data at ESMO demonstrating significant improvement in PFS regardless of baseline liver tumor burden

· Lutathera treatment was associated with an ~80% reduction in the estimated risk of tumor progression or death vs comparator, regardless of baseline liver...
GlobeNewswire - Press ReleasesAlso reported by •Proactive Investors

You Might Like


Tweets about this


Other recent news in Press Releases

GLOBAL IIoT Market in the Automotive Industry 2017-2021| Adoption of Virtual Reality Drives Growth| TechnavioKSEE24, Your LOCAL ELECTION Headquarters, Announces Series of California Debates
YOGI ADITYANATH Biography by Writer Pravin Kumar is Now in HindiFormer Mrs. USA to Act as Liaison for FLORIDA Premiere of Film, ‘Miss Arizona’
Environmentally friendly: One News Page is hosted on servers powered solely by renewable energy
© 2018 One News Page Ltd. All Rights Reserved.
About us  |  Contact us  |  Disclaimer  |  Press Room  |  Terms & Conditions  |  Content Accreditation
 RSS  |  News for my Website  |  Free news search widget  |  Contact us  |  DMCA / Content Removal  |  Privacy & Data Protection Policy
How are we doing? Send us your feedback  |   LIKE us on Facebook   FOLLOW us on Twitter  •  FOLLOW us on Pinterest